The Company

Chemomab Completes Merger with Anchiano Therapeutics (READ MORE) (March 16, 2021)
– Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol “CMMB
– Combined company will focus on advancing Chemomab’s CM-101 currently in Phase 2 for rare fibrotic indications

Visit Chemomab online at 

Our Mission:

We are Anchiano Therapeutics, a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer.

Our Science:  

Preclinical Programs:  

  • Small molecule pan-RAS inhibitors
  • Small molecule PDE10/ß-catenin inhibitors

We have a partnership with ADT Pharmaceuticals around two small molecule development programs targeting oncogenic pathways, focused on RAS and PDE10/ß-catenin, respectively.

Pan-RAS Program: Oncogenic mutations in the RAS family of genes (KRAS, HRAS, and NRAS) are present in approximately 30% of cancer. RAS plays a pivotal role in signal transduction pathways leading to tumor cell proliferation and survival. Our program has identified novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation, or pan-RAS inhibition.

PDE10/ß-catenin Program: Genetic alterations in components that make up the Wnt signaling pathway, which includes APC (adenomatous polyposis coli) and β-catenin, are prevalent in a number of cancer types, occurring in upwards of 80% of colorectal cancers. Our program has identified small molecules that selectively and potently inhibit PDE10 and suppress Wnt/β-catenin signaling in preclinical models. PDE10 inhibition has been shown to down regulate β-catenin expression and inhibits polyp and tumor growth. It has potential for application in the treatment of cancer as well as spontaneous and familial polyposis syndromes.

Our Core Values:

  • Science – we are dedicated to the highest level of scientific innovation and research.
  • Compassion – we value life and we devote our resources to its preservation and improvement.
  • Excellence – we set high standards and pursue our work with passion. 
  • Achievement – we set aggressive goals with confidence in our ability and perseverance to achieve them.
  • Integrity – we conduct ourselves with honesty and the highest ethical standards. 
  • Focus on Patients – we are committed to the development of novel therapies that benefit patients and society. 

We are located in Cambridge, Massachusetts and are publicly traded on the Nasdaq (NASDAQ: ANCN).